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a b s t r a c t
In 2017, WHO convened a working group of global experts to develop the Preferred Product
Characteristics (PPC) for Next-Generation Influenza Vaccines. PPCs are intended to encourage innovation
in vaccine development. They describe WHO preferences for parameters of vaccines, in particular their
indications, target groups, implementation strategies, and clinical data needed for assessment of safety
and efficacy. PPCs are shaped by the global unmet public health need in a priority disease area for which
WHO encourages vaccine development. These preferences reflect WHO’s mandate to promote the devel-
opment of vaccines with high public health impact and suitability in Low- and Middle-Income Countries
(LMIC). The target audience is all entities intending to develop or to achieve widespread adoption of a
specific influenza vaccine product in these settings. The working group determined that existing influ-
enza vaccines are not well suited for LMIC use. While many developed country manufactures and
research funders prioritize influenza vaccine products for use in adults and the elderly, most LMICs do
not have sufficiently strong health systems to deliver vaccines to these groups. Policy makers from
LMICs are expected to place higher value on vaccines indicated for prevention of severe illness, however
the clinical development of influenza vaccines focuses on demonstrating prevention of any influenza ill-
ness. Many influenza vaccine products do not meet WHO standards for programmatic suitability of vac-
cines, which introduces challenges when vaccines are used in low-resource settings. And finally, current
vaccines do not integrate well with routine immunization programs in LMICs, given age of vaccine licen-
sure, arbitrary expiration dates timed for temperate country markets, and the need for year-round immu-
nization in countries with prolonged influenza seasonality. While all interested parties should refer to the
full PPC document for details, in this article we highlight data needs for new influenza vaccines to better
demonstrate the value proposition in LMICs.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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1. Background
Influenza causes substantial death and suffering and has signif-
icant socioeconomic implications [1]. The World Health Organiza-
tion (WHO) recommends that countries use influenza vaccine in
high risk individuals, including pregnant women, children aged
6–59 months, elderly adults, individuals with specific chronic
medical conditions, and health-care workers to prevent severe ill-
ness and death [1]. Influenza vaccines are reformulated up to twice
yearly and are of modest effectiveness against influenza illness.
The continuous mutations of circulating influenza viruses and the
limited duration of vaccine protection necessitate that high-risk
persons be vaccinated annually. High-income countries use most
of the influenza vaccines that are distributed globally [2,3], while
many low- and middle-income countries (LMICs) do not have
national influenza vaccine programs [3]. Available influenza vacci-
nes may not meet the expectations or programmatic needs of
LMICs, and the data in support of their use may be insufficient
for LMIC policy makers.
2. WHO preferred product characteristics
Improved influenza vaccines that meet the needs of LMICs
are critically needed. In 2017, WHO developed Preferred Product
Characteristics for Next-Generation Influenza Vaccines to encourage
innovation in influenza vaccine development [4]. Preferred pro-
duct characteristics (PPCs) describe WHO preferences for vaccine
indications, target groups, implementation strategies, and clini-
cal data needed for assessment of product safety and efficacy
[5].
PPCs are shaped by the global unmet public health need in a pri-
ority disease area for which WHO encourages vaccine develop-
ment. These preferences reflect WHO’s mandate to promote the
development of vaccines with high public health impact and suit-
ability in LMICs. The target audience is all entities intending to
develop or to achieve widespread adoption of a specific influenza
vaccine product in these settings.
3. Unmet global public health need and use case
WHO convened an advisory group of international experts on
influenza vaccines and public health to develop the PPC document.
The PPC Advisory Group developed a consensus statement on the
global public health need for improved influenza vaccines:
Safe and well-tolerated influenza vaccines that prevent severe
influenza illness, provide protection beyond a single year, and are
suitable for programmatic use, are needed for low- and middle-
income countries.
The WHO position on influenza vaccines and the global unmet
public health need define a use case that is prioritized – the pre-
vention of severe seasonal influenza illness through routine immu-
nization of high-risk groups in LMICs which have existing systems
for vaccine delivery. The high risk groups for which improved
influenza vaccines are most needed are young children and older
adults, as influenza vaccine effectiveness is suboptimal in these
groups [6]. The PPC Advisory Group considered immunization
strategies timed with existing immunization contacts, such as
the routine childhood vaccination schedule or antenatal care.
Given the limitations in immunization systems for adults in low-
resource settings [7], the priority target group of the PPC docu-
ment therefore is young children, defined as those younger than
five years of age, with immunization of other risk groups as a sec-
ondary target.
4. Strategic goals
The PPC defines strategic goals for five- and ten-year time hori-
zons and the preferred vaccine characteristics to address each
strategic goal. The document development was guided by
evidence-based assumptions with regard to vaccine research and
development as well as availability of immunization services
within these time horizons. The strategic goals take into account
burden of disease, likelihood of product availability, and the prac-
tical realities of immunization systems in LMICs. The first strategic
goal specifies vaccine improvements by 2022:
By 2022, greater protection against vaccine-matched or drifted
influenza strains than provided by currently prequalified non-
adjuvanted non-replicating influenza vaccines, and protection
against severe influenza for at least one year, will have been
demonstrated for seasonal influenza vaccines that are suitable for
high-risk groups in low- and middle-income countries.
This strategic goal promotes the evaluation of currently avail-
able vaccines and vaccine technologies to demonstrate product
characteristics and feasibility of use that would align with the glo-
bal unmet public health need. A second strategic goal specifies vac-
cine improvements by 2027:
By 2027, influenza vaccines that have the potential to provide pro-
tection against severe influenza A virus illness for at least five years,
and are suitable for high-risk groups in low- and middle-income
countries, will be in advanced clinical development.
This strategic goal promotes research and development of prod-
ucts that are aligned with the global unmet public health need.
5. Key findings of the advisory group
The full PPC document is available on the WHO website [8]. It
includes an expanded rationale, procedures followed, assumptions,
and vaccine characteristic parameters for each strategic goal.
Specific product parameters include indication, target population,
safety, co-administration with other vaccines, duration of protec-
tion, outcome measures and efficacy, immunogenicity, registra-
tion, prequalification for procurement by United Nations
agencies, programmatic suitability, and value proposition. The doc-
ument highlights gaps in data needed by LMIC policy makers. Fully
addressing certain gaps, such as the ten-year goal of development
of an influenza vaccine that can prevent illness up to five years
after a primary series, will likely require more extensive research
and additional product development. Other gaps, such as age de-
escalation studies to facilitate integration of influenza vaccination
into routine pediatric immunization schedules, can be pursued
already with existing products. While all interested parties should
refer to the full PPC document for details, key conclusions are high-
lighted below.
5.1. Vaccine delivery systems are limited in many countries
While scant information is available regarding the burden of
severe influenza in high-risk groups in most LMIC settings, data
from high-income countries indicate that adults with chronic med-
ical illness and older adults bear the highest burden of influenza
mortality [9]. However, these age groups do not have established
vaccine delivery systems in many LMICs. In these countries, health
systems are typically able to provide vaccination through national
childhood immunization programs which target children <2 years
of age, antenatal care programs, and HPV vaccination programs
targeting girls from 9 years of age. While providing vaccination
across the entire life course is a global priority [7], more work is
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needed to strengthen adult immunization systems. Any entity
advocating influenza vaccine use in LMICs must be aware of the
limitations of health systems to deliver immunization services to
adults.
5.2. Data on the impact of influenza vaccination on severe illness are
needed
Policy makers from LMICs are expected to place higher value on
vaccines indicated for prevention of severe illness. High quality
data on the impact of influenza vaccines on severe illness in these
settings are extremely limited. Severe illness clinical endpoints
should be developed which are generalizable, feasibly applicable
in studies conducted in LMIC settings, and reproducible. Well-
designed studies demonstrating influenza vaccine impact on
important public health outcomes would strengthen the case for
their use globally. An influenza vaccine clinical trial in LMICs with
demonstration of vaccine efficacy against severe illness would sub-
stantially influence how influenza vaccines are used globally [10].
5.3. Influenza vaccines must meet the programmatic needs of
immunization programs
Vaccine developers should be aware of the call from immuniza-
tion programs in resource-poor settings that innovation related to
programmatic suitability, such as ease of administration and ther-
mostability, would lead to major public health benefits. Advances
that are achievable in the next decade include greater availability
of needle-free administration for vaccine delivery and improved
thermostability to obviate the need for a refrigerated cold chain.
Widespread integration of influenza vaccines into routine pediatric
programs in LMICs will require decreased age for licensure and
possibly changes in vaccine presentation and packaging to adhere
to current WHO guidelines for programmatic suitability [11]. For
immunization programs in countries with prolonged or atypical
influenza seasons, addressing the gaps in vaccine availability
caused by fixed expiration dates and manufacturing schedules
designed for temperate countries could be transformative.
5.4. Existing options should be tested and utilized
Although broad-spectrum influenza vaccines which confer
long-lasting immunity may not be licensed for many years [12],
much can be done in the short term to ensure evaluation and
optimal use of existing vaccines and to adapt or modify current
influenza vaccine technologies and vaccination strategies.
Available influenza vaccine technologies including adjuvanted,
live-attenuated, intradermal, microneedle patches, or high-dose
vaccines may meet some or all of the PPC criteria and should be
evaluated for use in LMICs.
6. Conclusion
The PPC document describes preferences for parameters of
influenza vaccines to prevent severe influenza illness in LMICs.
To date, the evidence in support of influenza vaccine program
impact has not sufficiently demonstrated the value proposition of
their routine use in LMIC settings. Data on additional clinical out-
comes, including severe illness, are needed if influenza vaccines are
to be prioritized by LMICs for use. While it would be a major public
health achievement if a vaccine product were demonstrated to
meet all of the five-year or ten-year strategic goal parameters,
demonstration of one or more of the recommended PPC character-
istics for an influenza vaccine product would be of high value for
public health. For all entities desiring to expand routine influenza
vaccines use or to strengthen pandemic influenza vaccine pre-
paredness in LMICs, we advise consideration of the WHO influenza
vaccine product preferences.
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